Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie’s profit beats analysts’ expectations

U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.

Read More »

CMOs Cringe as GlaxoSmithKline Will be Cutting Its Use by 25%

GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.

Read More »

Bristol-Myers shares slump after rival’s failed study

Bristol-Myers Squibb shares fell as a failed cancer-drug trial at AstraZeneca could have negative implications for its similar immunotherapy treatment regimen.

Read More »

Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma

While reporting strong earnings, New Haven, Conn.-based Alexion Pharmaceuticals also indicated the company plans to retool its research-and-development strategy.

Read More »

AstraZeneca lung cancer failure sparks share fall

AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares.

Read More »

GlaxoSmithKline’s new boss streamlines R&D

GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.

Read More »

Eli Lilly Shakes Up Cancer R&D Strategy

Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.

Read More »

Ironwood’s Potential Blockbuster Drug Meets Main Goals in Mid-Stage Trial

Ironwood Pharmaceuticals touted its Phase IIb drug candidate IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease (GERD), but investors seem wary as share prices were down more than 7 percent.

Read More »

Novartis Boss Updates Q2 2017 Financials, Reaffirms M&A Strategy

Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.

Read More »

Valeant Dumps Another Asset in Cash Deal

Valeant Pharmaceuticals is selling its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I for $190 million in cash.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom